Upcoming Global Web Symposia
Wednesday, August 18
11:30 am - 1:00 pm EST
John C Erve, Ph.D., D.A.B.T., Independent Pharmaceutical Research Consultant, Former Principal Research Scientist II, Pfizer Inc.
Course DescriptionMany drugs withdrawn from the market for toxicity reasons have later been shown to undergo bioactivation to reactive intermediates. Still, there remain unanswered questions regarding the relationship between reactive metabolites and idiosyncratic toxicity. For example, although the issue of protein binding has been recognized for decades, the exact mechanisms leading to drug toxicity are still being worked out. Strategies that medicinal chemists employ in designing drugs with the best safety profile should incorporate our current understanding of structure-toxicity relationships and should also reflect our knowledge about the relationship of dose and risk of idiosyncratic toxicity. Newer tools such as in silico modeling of drug metabolism can also address bioactivation issues and may be a valuable tool to help design safer drugs.
Who Should Attend
Instructor BiographyJohn is a pharmaceutical professional with 15 years of diverse scientific experience encompassing drug discovery and early clinical development, primarily in the area of drug biotransformation. As a former member of the Biotransformation Group at Pfizer, he was involved in performing metabolite identification studies of over a dozen compounds for advancement to clinical development. He has extensive experience using mass spectrometry to identify metabolites in preclinical toxicology species as well as from first in human studies.
John received his Ph.D. in Toxicology from Oregon State University, and completed a postdoctoral fellowship in the Dept. of Pathology at the Vanderbilt University School of Medicine and center for Molecular Toxicology. He is the author of numerous publications and is also a Diplomat of the American Board of Toxicology.
250 First Avenue Suite 300Needham, MA 02494P: 781.972.5400F: 781.972.5425E: firstname.lastname@example.org
biological therapeutic productsbiomarkers & diagnosticsbiopharma strategybioprocess & manufacturingchemistryclinical trials & translational medicinedrug & device safety
drug discovery & developmentdrug targetsgenomicshealthcareit & informaticstechnology & tools for life sciencetherapeutic indications
conferencesreportsbarnett educational servicesconsulting
publications & eNewsletters
executive teamtestimonialschi timelinemailing listcareers